At the three-month mark, conduct your first formal assessment
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
10.1164/rccm.200806-851OC Summary Keywords glutathione peroxidase, redox balance, oxidative stress, inflammation, iron death Citation Pei J, Pan X, Wei G and Hua Y (2023) Research progress of glutathione peroxidase family (GPX) in redoxidation
The prescription should specify the dose for each route and should not imply that the same dose can be given by mouth or by intramuscular injection